Last reviewed · How we verify

MenC

Novartis Vaccines · FDA-approved active Biologic Quality 46/100

MenC stimulates the immune system to produce antibodies against the capsular polysaccharide of Neisseria meningitidis serogroup C.

MenC, developed by Novartis Vaccines, is a vaccine designed to prevent meningococcal disease caused by Neisseria meningitidis serogroup C. The vaccine works by stimulating the immune system to produce antibodies against the bacterial capsular polysaccharide. Despite its efficacy, MenC does not have an FDA label, indicating it may be approved in other regions or used under specific circumstances. Common side effects include injection site reactions and mild fever. The vaccine is generally well-tolerated, but contraindications and precautions should be considered before administration.

At a glance

Generic nameMenC
SponsorNovartis Vaccines
Drug classConjugate vaccine
TargetCapsular polysaccharide of Neisseria meningitidis serogroup C
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The vaccine contains purified capsular polysaccharide from Neisseria meningitidis serogroup C, which acts as an antigen to elicit an immune response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: